Results 81 to 90 of about 101,700 (245)
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]
, 2016 Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet +9 more
core +1 more source
Journal of Surgical Oncology, EarlyView.ABSTRACT Background and Objectives Succinate dehydrogenase‐deficient (SDH‐deficient) gastrointestinal stromal tumors (GIST) are characterized by variable disease biology with poor responses to traditional tyrosine kinase inhibitors. The role of surgical intervention has been highly debated.
Katherine Y. Chen +6 more
wiley +1 more source
The changing face of cancer therapeutics improved : outcome and decreased toxicity with Molecular Targeted Drugs [PDF]
, 2004 The treatment of patients with cancer has largely involved the administration of cytotoxic drugs with narrow therapeutic indices, with little selectivity for cancer cells over normal proliferating cells.
Attard, Gerhardt, De Bono, Johann S.
core
National Institute for Clinical Excellence and its value judgments [PDF]
, 2004 The National Institute for Clinical Excellence (NICE) offers health professionals in England and Wales advice on providing NHS patients with the highest attainable standards of care.
Culyer, A.J., Rawlins, M.D.
core +2 more sources
Non-Hodgkin's lymphoma in a chronic myelocytic leukemia patient treated with imatinib
Turkish Journal of Hematology, 2011 Imatinib is an important example of tyrosine kinase inhibitors (TKIs) used in clinical practice. Imatinib blocks the ATP binding site of the Bcr-Abl fusion protein and selectively inhibits Bcr-Abl tyrosine kinase (TK) activity.
Semra Paydaş +2 more
doaj +3 more sources
Proteomes, 2014 Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases.
Katerina Arvaniti +5 more
doaj +1 more source
Long-term follow-up of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period [PDF]
, 2005 Chronic myeloid leukaemia (CML) is rare in childhood. In our Institution we managed 30 consecutive Ph+CML patients aged
DE CUIA MR +7 more
core +1 more source
Molecular Carcinogenesis, EarlyView.ABSTRACT Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer. Despite recent advances in treating BRAFV600E‐driven ATC, therapy resistance remains a significant challenge, often resulting in disease progression and death.
Shawn Noronha +26 more
wiley +1 more source
Journal of Translational MedicineBackground Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal sarcomas of the upper digestive tract. Imatinib is the first-line therapy for patients with metastatic or unresectable GISTs.
Hanxing Tong +8 more
doaj +1 more source
Relation of common ABL kinase domain mutations with resistance to Tyrosine Kinase Inhibiters in patients with Chronic Myeloid Leukemia in Middle Euphrates of Iraq [PDF]
, 2020 Background: Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease, associated with a reciprocal translocation between chromosomes 9 and chromosome 22, lead to the formation of the BCRABL fusion gene (Philadelphia chromosome).
Musawi, Mohammed Sadeq Mahdi Al-
core